| 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to reach sustained profitability; our ability to continue to generate sales of our commercialized products; our ability to successfully develop and commercialize additional products; our ability to obtain acceptance of our products globally and effectively grow our global sales and marketing organization; the material disruption of the supply and/or manufacture of our iStent, iStent inject and Photrexa therapies, or our other commercialized products; our ability to meet our customers’ quality and delivery expectations; the impact of epidemic diseases, such as coronavirus, on our operations; our ability to secure and maintain adequate coverage or reimbursement by government or other third-party payors for procedures using our products; the reduction or elimination of our commercial opportunity if our competitors develop and market products that are safer, more effective, less costly or otherwise more attractive than our products; our ability to adequately train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; the impact of any product liability suits against us and any related litigation; the impact of operating results that could fluctuate significantly from quarter to quarter; our ability to meet customer demand if growth and manufacturing capability is not effectively managed; our ability to recruit and maintain qualified and key employees and members of our senior management team; the effect of some of our expanded product offerings being regulated as drugs and subject to different regulatory requirements; uncertainty of the success of acquisitions, collaborations, in-licensing agreements and joint ventures with third parties; our ability to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions or data corruption; our ability to comply with data privacy and security laws; the availability of net operating loss tax carryforwards to offset future taxable income; the expense and uncertainty of navigating extensive federal, state and foreign regulatory authorities’ regulations; the impact of legislative or regulatory reform of the healthcare system; the risks associated with expanding our international operations; the complexity and expense of complying with environmental laws; our ability to adequately protect our intellectual property; the timing, effect, expense and uncertainty of patent and other intellectual property litigation or administrative proceedings we have been and may in the future become involved in; the risks associated with a company-wide implementation of an enterprise resource planning system. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (the “SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 2, 2020. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this presentation are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. |
